A future coronavirus vaccine may want to be administered every 12 weeks, the pharmaceutical giant AstraZeneca cautioned Thursday.The British company is only 1 firm working on an expected coronavirus vaccine. It stated Thursday the late-stage trials are occurring from the UK., Brazil and South Africa and will start in the USA too. These evaluations are aimed at confirming the way the immune system reacts to this vaccine. Before this month, its own vaccine, which has been developed by Oxford University, generated a “promising” immune reaction in big, early-stage human trials. Due to the unpredictability of Covid-19, the pharmaceutical company increased the chance that more than 1 shot may be required later on, if their job does prove effective. “What we understand is that most businesses are targeting two shots for the first vaccination and our very own premise based on what we understand from the tech we utilize with SARS 1 is the resistance could survive 12 months possibly 18 months,” Pascal Soriot, chief executive officer of AstraZeneca, told CNBC’s “Squawk Box Europe.””However, the reality is that we do not understand , this virus is very unpredictable,” he added.The company has reached deals to distribute its potential Covid-19 vaccine in different parts of the world. In Junefor instance, it reached an agreement with Europe’s Inclusive Vaccines Alliance, supported by Germany, France, Italy and the Netherlands, to supply up to 400 million doses. It’s aiming to produce 2 billion in total, including 400 million doses for the U.S. and UK. and 1 billion for low- and middle-income countries.”We have set up supply chains independently from each other,” Soriot told CNBC, reaffirming a commitment to provide their work all over earth.”If it does work, we will be able to start supplying the vaccine in October, November and our goal is to provide everyone around the world at the same time,” he said.AstraZeneca reported Thursday higher revenues and – product sales during precisely the next quarter of this year. The company registered growth in each therapeutic area in addition to geographical region. Shares were trading 2% greater in the first morning session around the united kingdom.’s FTSE 100 indicator.